
price close busi juli
biomed devic servic
sign slow stay cours buy
bottom line follow stellar anoth quarter record new patient
addit revenu growth y/i support strong growth
sensor volum offset price pressur hardwar increas global
adopt cgm on-going uptak look forward continu
drive patient awar expect robust new patient addit
persist year-end ye investor sentiment continu impact abbott
impend approval/launch next gener libr rais concern
regard stabil lt price margin note overhang like
persist fda approv hand better idea full clinic util
 accuraci cgm statu regardless continu believ market
larg enough support multipl player global finger-stick test coalesc around
player manufactur focu product pipelin posit
compani strong line-up fulli equip lower cost technolog said
expect share volatil continu base competit product approv suggest
investor use opportun build add posit sum remain
bullish near- long-term product pipelin grow opportun
deliv upsid expect beyond buy
result releas revenu y/i cg/
consensu expect us sale grew y/
benefit continu increas market awar accept cgm
manag note ou revenu flat sequenti due time
distributor order ou flow distributor channel note
revenu still grew y/i global penetr remain earli day gm
estim y/i due headwind
increas invest scale infrastructur drive capac expans
continu shift mix toward pharmaci channel
except start manag highlight continu robust demand
new system support improv market awar accept
cgm note us patient cover pharmaci channel
lower barrier adopt patient physician come
expens near-term revenu tune headwind
realiz ytd said headwind appear impact
abil grow revenu volum growth continu off-set
anticip price pressur though note comp get consider tougher
second half lap first full year market addit
expect recent partnership/integr announc tandem pump companion
medic inpen etc continu drive consider new patient growth
back half year
continu invest futur growth remain track doubl
product capac end increas invest weigh gm
manag reiter manufactur improv effort lower
transmitt cost expect cost less produc back half
track put back near exit lastli compani continu invest
remain track limit launch late ahead full launch
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
guidanc chang estim
lift revenu guidanc growth
 growth gross margin guidanc
maintain rang non-gaap om guidanc increas
non-gaap adjust ebitda margin guidanc lift
made follow chang estim
figur summari estim revis
buy unchang target price juli
biomed devic servic
resultsactualcg estbeat/miss beat/miss consensusbeat/miss total revenu total gross oper oper net result categoryactualcg estbeat/missbeat/miss prior yeary/i growthnet sale except ep newold newold newold product
high-growth med-tech comp group current trade mean ev/sal multipl
estim revenu sum increas price target base
ev/sal multipl appli revenu estim
price target assum cash debt share
outstand
figur matrix discount rate impli share price target
buy unchang target price juli
biomed devic servic
discount comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price juli
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price juli
biomed devic servic
